Arnold Lippa
Directeur Général chez RESPIRERX PHARMACEUTICALS INC.
Fortune : 9 $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jeff Margolis | M | 68 |
Atypical BioCapital Management LLC
Xintria Pharmaceutical Corp.
Atypical BioVentures Fund, LLC
| 20 ans |
G. Robert Abrams | M | - |
Aurora Capital LLC
Aurora Capital LLC Investment Banks/BrokersFinance Aurora Capital LLC engages in providing investment banking services. It offers private placement, bridge finance, merger & acquisition, joint venture and technology transfer services. The company was founded in 1994 by Jeff Eliot Margolis and John F. McGovern and is headquartered in New York, NY. | 19 ans |
John F. McGovern | M | 78 |
Aurora Capital LLC
Aurora Capital LLC Investment Banks/BrokersFinance Aurora Capital LLC engages in providing investment banking services. It offers private placement, bridge finance, merger & acquisition, joint venture and technology transfer services. The company was founded in 1994 by Jeff Eliot Margolis and John F. McGovern and is headquartered in New York, NY. | 25 ans |
Joseph R. Siegelbaum | M | - | 1 ans | |
John Cavan | M | 65 | 8 ans | |
Kaouthar Lbiati | M | 45 | 2 ans | |
Marc M. Radin | M | - | 11 ans | |
Richard Purcell | M | 63 | 10 ans | |
Daren Ure | M | - | 5 ans | |
Daniel Trepanier | M | - | 5 ans | |
David Dickason | M | - | 4 ans | |
Dariusz Nasiek | M | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Mark A. Varney | M | 57 | 7 ans | |
Robert Foster | M | 65 | 7 ans | |
Kathryn MacFarlane | M | 58 |
Xintria Pharmaceutical Corp.
| 11 ans |
James Sapirstein | M | 63 | 5 ans | |
James Manuso | M | 75 | 3 ans | |
Timothy Jones | M | - | 2 ans | |
Charles Casamento | M | 78 | 16 ans | |
Barbara Duncan | F | 59 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 8 ans |
Peter Wijngaard | M | 61 | 3 ans | |
Christopher McGuigan | M | 65 | 3 ans | |
M. Ross Johnson | M | 79 | 11 ans | |
Theresa Matkovits | M | 56 | 3 ans | |
Anand Reddi | M | 42 | 2 ans | |
Tamar Howson | F | 75 | 2 ans | |
Phil Skolnick | M | 77 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 8 ans |
Thomas H. Adams | M | 81 | 6 ans | |
John F. Benedik | M | 76 | 8 ans | |
Robert Weingarten | M | 72 | 4 ans | |
Jonathan Guarino | M | 51 | 3 ans | |
Todd Hobbs | M | 55 | 2 ans | |
Scott Myers | M | 57 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 2 ans |
Patrick Mayo | M | - | 5 ans | |
Stuart Apfel | M | 63 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 2 ans |
Zola P. Horovitz | M | 89 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
John Z. Sullivan-Bólyai | M | 76 | 2 ans | |
Robert Keyser | M | - |
Aurora Capital LLC
Aurora Capital LLC Investment Banks/BrokersFinance Aurora Capital LLC engages in providing investment banking services. It offers private placement, bridge finance, merger & acquisition, joint venture and technology transfer services. The company was founded in 1994 by Jeff Eliot Margolis and John F. McGovern and is headquartered in New York, NY. | 2 ans |
Launa J. Aspeslet | M | - | 2 ans | |
Theresa A. Bischoff | F | 69 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
Robert LeBoyer | M | - |
Aurora Capital LLC
Aurora Capital LLC Investment Banks/BrokersFinance Aurora Capital LLC engages in providing investment banking services. It offers private placement, bridge finance, merger & acquisition, joint venture and technology transfer services. The company was founded in 1994 by Jeff Eliot Margolis and John F. McGovern and is headquartered in New York, NY. | 4 ans |
Jonathan Silverstein | M | 57 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
Patrick Ashe | M | 59 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 11 ans |
J. Robert Horton | M | 88 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
Moogak Hwang | M | - | 1 ans | |
Leslie Hudson | M | 76 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 1 ans |
Daniel S. van Riper | M | 83 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 6 ans |
Warren C. Stern | M | 79 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 48 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Arnold Lippa
- Réseau Personnel